The javascript used on this site for creative design effects is not supported by your browser. Please note that this will not affect access to the content on this web site.
Skip Navigation
H H S Department of Health and Human Services
Health Resources and Services Administration
HIV/AIDS Programs

A-Z Index  |  Questions? 

The HAB website will experience a temporary service outage on Saturday, July 2, 2016 for scheduled server maintenance. We apologize for the inconvenience.
  • Print this
  • Email this

SPNS Initiative: An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Abuse Treatment in HIV Primary Care Settings, 2004-2009

Background

The Special Projects of National Significance (SPNS) Buprenorphine Initiative was designed to determine the feasibility and effectiveness of integrating buprenorphine opioid abuse treatment into HIV primary care settings with an ultimate goal of improving the health of people living with HIV and opioid dependency.  This initiative began in September 2004 and was led by the New York Academy of Medicine (NYAM), which served as the Evaluation and Technical Assistance Center.  NYAM coordinated the multi-site evaluation of the demonstration sites and provided them with technical assistance.  

The ten demonstration project grant recipients included:  The Miriam Hospital (Providence, RI); El Rio Santa Cruz Neighborhood Health Center (Tucson, AZ); The Hektoen Institute (Chicago, IL); Johns Hopkins School of Medicine (Baltimore, MD); Montefiore Medical Center (Bronx, NY); OASIS (Oakland, CA); Oregon Health and Science University (Portland, OR); University of California, San Francisco; University of Miami (Miami, FL); and Yale University (New Haven, CT).

Journal Articles

Tetrault JM, McCance-Katz EF, Moody DE, Fiellin DA, Lruie BS, DInh AT, & Fiellin LE.  The Impact of Recent Cocaine Use on Plasma Levels of Methadone and Buprenorphine in Patients with and Without HIV-infection.  Journal of Substance Abuse Treatment, April 2015; 51: 70-74. PubMed Abstract

Cunningham CO, Giovanniello A, Li X, Kunins HV, Roose RJ, & Sohler NL. A comparison of buprenorphine induction strategies: Patient-centered home-based inductions versus standard-of-care office-based inductions. Journal of Substance Abuse Treatment, June 2011; 40(4): 349-356. PubMed Abstract

Friedland G and Vlahov D. Integration of Buprenorphine for Substance-Abuse Treatment by HIV Care Providers. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S1-S2. No abstract available.

Cheever LW, Kresina TF, Cajina A, & Lubran R. A Model Federal Collaborative to Increase Patient Access to Buprenorphine Treatment in HIV Primary Care. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S3-S6. PubMed Abstract

Weiss L, Egan JE, Botsko M, Netherland J, Fiellin D, Finkelstein R. The BHIVES Collaborative: Organization and Evaluation of a Multisite Demonstration of Integrated Buprenorphine/Naloxone and HIV Treatment.  Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S7-S13.  PubMed Abstract

Chaudhry AA, Botsko M, Weiss L, Egan JE, Mitty J, Estrada B, Lucas GM, Woodson T, Flanigan TP, & Fiellin DA, for the BHIVES Collaborative. Participant Characteristics and HIV Risk Behaviors Among Individuals Entering Integrated Buprenorphine/Naloxone and HIV Care. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S14-S21. PubMed Abstract

Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R, and the BHIVES Collaborative (2011) HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S22-S32. PubMed Abstract

Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, & O'Connor PG, for the BHIVES Collaborative. Drug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S33-S38. PubMed Abstract

Korthuis PT, Tozzi MJ, Nandi V, Fiellin DA, Weiss L, Egan JE, Botsko M, Acosta A, Gourevitch MN, Hersh D, Hsu J, Boverman J, & Altice FL, for the BHIVES Collaborative.  Improved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S39-S45. PubMed Abstract

Egan JE, Netherland J, Gass J, Finkelstein R, & Weiss L, for the BHIVES Collaborative. Patient Perspectives on Buprenorphine/Naloxone Treatment in the Context of HIV Care. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S46-S53. PubMed Abstract

Sullivan LE, Botsko M, Cunningham CO, O'Connor PG, Hersh D, Mitty J, Lum PJ, Schottenfeld RS, & Fiellin DA, for the BHIVES Collaborative. The Impact of Cocaine Use on Outcomes in HIV-Infected Patients Receiving Buprenorphine/Naloxone. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S54-S61. PubMed Abstract

Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, Egan JE, O'Connor PG, Sullivan LE, & Fiellin DA, for the BHIVES Collaborative. Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S62-S67. PubMed Abstract

Weiss L, Netherland J, Egan JE, Flanigan TP, Fiellin DA, Finkelstein R, & Altice FL, for the BHIVES Collaborative.  Integration of Buprenorphine/Naloxone Treatment into HIV Clinical Care: Lessons From the BHIVES Collaborative. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S68-S75. PubMed Abstract

Schackman BR, Leff JA, Botsko M, Fiellin DA, Altice FL, Korthuis PT, Sohler N, Weiss L, Egan JE, Netherland J, Gass J, & Finkelstein R, for the BHIVES Collaborative. The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S76-S82. PubMed Abstract

Korthuis PT, Fiellin DA, Fu Rongwei, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, & McCarty D, for the BHIVES Collaborative. Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S83-S90. PubMed Abstract

Lum PJ, Little S, Botsko M, Hersh D, Thawley RE, Egan JE, Mitty J, Boverman J, & Fiellin DA, for the BHIVES Collaborative. Opioid-Prescribing Practices and Provider Confidence Recognizing Opioid Analgesic Abuse in HIV Primary Care Settings. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S91-S97. PubMed Abstract

Finkelstein R, Netherland J, Sylla L, Gourevitch MN, Cajina A, Cheever L, for the BHIVES Collaborative. Policy Implications of Integrating Buprenorphine/Naloxone Treatment and HIV Care. Journal of Acquired Immune Deficiency Syndromes, March 2011; 56 (Supplement 1): S98-S104. PubMed Abstract

Whitley SD, Sohler NL, Kunins HV, Giovanniello A, Li X, Sacajiu G, & Cunningham CO. Factors associated with complicated buprenorphine inductions. Journal of Substance Abuse Treatment, July 2010; 39(1): 51-57. PubMed Abstract

Sohler NL, Li X, Kunins HV, Sacajiu G, Giovanniello A, Whitley S, & Cunningham CO.  Home- versus office-based buprenorphine inductions for opioid-dependent patients. Journal of Substance Abuse Treatment, March 2010; 38(2): 153-159.  PubMed Abstract

Cunningham CO, Giovanniello A, Sacajiu G, Li X, Brisbane M, & Sohler NL. Inquiries about and initiation of buprenorphine treatment in an inner-city clinic. Substance Abuse, July-September 2009; 30(3): 261-262. PubMed Abstract

Netherland J, Botsko M, Egan JE, Saxon AJ, Cunningham CO, Finkelstein R, Gourevitch MN, Renner JA, Sohler N, Sullivan LE, Weiss L, Fiellin DA; and the BHIVES Collaborative.  Factors affecting willingness to provide buprenorphine treatment.  Journal of Substance Abuse Treatment, April 2009; 36 (3): 244-51.  PubMed Abstract

Cunningham CO, Kunins HV, Roose RJ, Elam RT, & Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. Journal of General Internal Medicine, September 2007; 22 (9): 1325-1329.  PubMed Abstract

Part F - SPNS Resources

Part F - SPNS Products and Publications

About SPNS

Products from SPNS Initiatives

TARGET Center Resource Exit Disclaimer

iHiP Exit Disclaimer

SPNS Staff

Adan Cajina
Branch Chief
acajina@hrsa.gov
301-443-3180

Pamela Belton
Public Health Analyst
pbelton@hrsa.gov
301-443-4461

Renetta Boyd
Public Health Analyst
rboyd@hrsa.gov
301-443-4549

Johanna Goderre
Health Scientist
JGoderreJones@hrsa.gov
301-443-7874

John Hannay
Public Health Analyst
jhannay@hrsa.gov
301-443-0678

Chau Nguyen
Public Health Analyst
cnguyen1@hrsa.gov
301-443-5785

Natalie Solomon
Public Health Analyst
nsolomon@hrsa.gov
301-443-7753

Melinda Tinsley
Public Health Analyst
mtinsley1@hrsa.gov
301-443-3496

Jessica Xavier
Health Scientist
jxavier@hrsa.gov
301-443-0833